Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | CPB1 | P15086 | 3/20 | 0.32 |
| ▸ | CPA1 | P15085 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23389223 | 0.79 | CPB2 (0.46) | CPB2ADORA2AADORA2BTLR7CPB1 | |
| SCHEMBL12448089 | 0.77 | CPB2 (0.39) | CPB2POLBADORA2AADORA2BLMNA | |
| SCHEMBL12224159 | 0.75 | CPB2 (0.38) | CPB2POLB | |
| SCHEMBL4909041 | 0.75 | CPB2 (0.38) | CPB2POLBCPB1 | |
| SCHEMBL27654362 | 0.75 | CPB2 (0.38) | CPB2POLBADORA2AADORA2BADORA1 | |
| SCHEMBL19867832 | 0.73 | CPB2 (0.54) | CPB2POLBCPB1 | |
| SCHEMBL3712700 | 0.73 | CYP2C9 (0.55) | CPB2POLBCPB1 | |
| SCHEMBL24925524 | 0.72 | — | — | |
| SCHEMBL12098968 | 0.72 | ADA (0.39) | LMNAPDE4DALDH1A1 | |
| SCHEMBL18250233 | 0.72 | CPB2 (0.37) | CPB2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023135950-A1 | PROTEOGLYCAN-CONTAINING IMMUNE RESPONSE MODIFIER | 一丸ファルコス株式会社 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023135949-A1 | PROTEOGLYCAN-CONTAINING IMMUNE RESPONSE MODIFIER | 一丸ファルコス株式会社 | 2023-07-20 | — | — | WO | disclosed |
| US-20210121562-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER | TORAY INDUSTRIES, INC. (JP) | 2021-04-29 | — | — | US | disclosed |
| CN-101850117-B | Compound immunologic adjuvant and vaccine | NAT CT FOR VETERINARY BIOLOG ENGINEERING RES | 2012-05-30 | — | — | CN | disclosed |
| CN-101850117-A | Compound immunological adjuvant and vaccine | NAT CT FOR VETERINARY BIOLOG ENGINEERING RES | 2010-10-06 | — | — | CN | disclosed |
| US-20080194822-A1 | Heating 4-chloro-1-isobutyl-1H-imidazo[4,5-c]quinoline with ammonia in a polar aprotic solvent to produce imiquimod; purification; industrial scale; dechlorination; precipitation, crystallization, slurrying, washing in a suitable solvent, filtration through a packed-bed column, dissolution in solvent | CHEMAGIS LTD. (IL) | 2008-08-14 | — | — | US | disclosed |
| EP-1831219-A2 | A PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE 4-AMINO-1-ISOBUTYL-1H-IMIDAZOÝ4,5-C¨-QUINOLINE (IMIQUIMOD) | USV LIMITED (IN) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006070408-A2 | A PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE 4-AMINO-1-ISOBUTYL-1H-IMIDAZO[4,5-C]-QUINOLINE (IMIQUIMOD) | USV LIMITED (IN) | 2006-07-06 | — | — | WO | disclosed |
| EP-0882727-B9 | NOVEL PURINE DERIVATIVES | SUMITOMO PHARMA (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-0882727-B1 | NOVEL PURINE DERIVATIVES | SUMITOMO PHARMA (JP) | 2004-12-01 | — | — | EP | disclosed |
| EP-0882727-A1 | NOVEL PURINE DERIVATIVES | JAPAN ENERGY CORPORATION (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0582581-A1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO 4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194822-A1 | Heating 4-chloro-1-isobutyl-1H-imidazo[4,5-c]quinoline with ammonia in a polar aprotic solvent to produce imiquimod; purification; industrial scale; dechlorination; precipitation, crystallization, slurrying, washing in a suitable solvent, filtration through a packed-bed column, dissolution in solvent | IMPDH1, IDO1, IPO4 | CPB2 3906/4885POLB 628/4885ADORA2A 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.